Yu Ning Wong

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi request reprint Survival associated with treatment vs observation of localized prostate cancer in elderly men
    Yu Ning Wong
    Division of Population Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    JAMA 296:2683-93. 2006
  2. pmc Correlates of colorectal cancer screening adherence among men who have been screened for prostate cancer
    Yu Ning Wong
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Cancer Educ 26:301-7. 2011
  3. pmc The role of primary androgen deprivation therapy in localized prostate cancer
    Yu Ning Wong
    Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Eur Urol 56:609-16. 2009
  4. pmc Role of androgen deprivation therapy for node-positive prostate cancer
    Yu Ning Wong
    Division of Population Science and Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 27:100-5. 2009
  5. pmc Cost implications of new treatments for advanced colorectal cancer
    Yu Ning Wong
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 115:2081-91. 2009
  6. doi request reprint Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model
    Alexander Kutikov
    Department of Urological Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania 19111, USA
    J Urol 188:2077-83. 2012
  7. pmc Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence?
    Yu Ning Wong
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111 2497, USA
    Oncologist 16:559-65. 2011
  8. pmc Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram
    Alexander Kutikov
    Department of Urological Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA 19111, USA
    J Clin Oncol 28:311-7. 2010
  9. pmc Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy
    Alexander Kutikov
    Department of Urological Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    BJU Int 106:218-23. 2010
  10. pmc Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network
    Rachel A Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Cancer 119:839-46. 2013

Collaborators

Detail Information

Publications29

  1. ncbi request reprint Survival associated with treatment vs observation of localized prostate cancer in elderly men
    Yu Ning Wong
    Division of Population Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    JAMA 296:2683-93. 2006
    ..Prostate-specific antigen screening has led to an increase in the diagnosis and treatment of localized prostate cancer. However, the role of active treatment of low- and intermediate-risk disease in elderly men is controversial...
  2. pmc Correlates of colorectal cancer screening adherence among men who have been screened for prostate cancer
    Yu Ning Wong
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Cancer Educ 26:301-7. 2011
    ..The prostate cancer screening encounter may represent a "teachable moment" to increase CRC screening rates...
  3. pmc The role of primary androgen deprivation therapy in localized prostate cancer
    Yu Ning Wong
    Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Eur Urol 56:609-16. 2009
    ..Primary androgen deprivation therapy (PADT) is frequently used as a sole modality of treatment in men with localized prostate cancer, despite a lack of clinical trial data supporting its use...
  4. pmc Role of androgen deprivation therapy for node-positive prostate cancer
    Yu Ning Wong
    Division of Population Science and Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 27:100-5. 2009
    ..To determine the impact of adjuvant androgen deprivation therapy (ADT) for patients who have node-positive prostate cancer in the prostate-specific antigen (PSA) era...
  5. pmc Cost implications of new treatments for advanced colorectal cancer
    Yu Ning Wong
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 115:2081-91. 2009
    ..The objective of the current study was to measure the cost implications of treatment with sequential regimens that include chemotherapy and/or monoclonal antibodies...
  6. doi request reprint Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model
    Alexander Kutikov
    Department of Urological Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania 19111, USA
    J Urol 188:2077-83. 2012
    ..These factors must be considered against the benefits of treatment. We constructed a model of competing causes of death to help contextualize treatment trade-off analyses in patients with localized renal cell carcinoma...
  7. pmc Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence?
    Yu Ning Wong
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111 2497, USA
    Oncologist 16:559-65. 2011
    ..Controlled clinical trials that establish a benefit from continued trastuzumab have been difficult to complete...
  8. pmc Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram
    Alexander Kutikov
    Department of Urological Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA 19111, USA
    J Clin Oncol 28:311-7. 2010
    ....
  9. pmc Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy
    Alexander Kutikov
    Department of Urological Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    BJU Int 106:218-23. 2010
    ....
  10. pmc Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network
    Rachel A Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Cancer 119:839-46. 2013
    ..The authors of this report examined receipt and completion of adjuvant trastuzumab by race/ethnicity and education for women with HER2-positive disease...
  11. doi request reprint Advanced imaging modalities in early stage breast cancer: preoperative use in the United States Medicare population
    Margaret L Crivello
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Ann Surg Oncol 20:102-10. 2013
    ..Guidelines for breast cancer staging exist, but adherence remains unknown. This study evaluates patterns of imaging in early stage breast cancer usually reserved for advanced disease...
  12. pmc Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis
    Benjamin J Scoll
    Department of Urologic Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania 19111, USA
    J Urol 181:506-11. 2009
    ..We analyzed data from the SEER (Surveillance, Epidemiology and End Results) database to evaluate the relative survival of patients treated surgically for localized renal cell carcinoma as related to tumor size and patient age...
  13. doi request reprint Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: A SEER database analysis
    Daniel Canter
    Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA Electronic address
    Urol Oncol 31:866-70. 2013
    ..We analyzed the Surveillance Epidemiology and End Results (SEER) database to ascertain the use of RC as an initial therapy for clinical HGT1 bladder cancer...
  14. pmc Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:5463-72. 2012
    ..The objective of this study was to describe clinicopathologic features, patterns of recurrence, and survival according to breast cancer subtype with a focus on triple-negative tumors...
  15. pmc Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis
    Jason Rothman
    Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    J Urol 181:29-33; discussion 33-4. 2009
    ..We determined whether a relationship exists between primary tumor size and histopathological features in cases of localized renal cancer...
  16. pmc Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer
    Michael J Hassett
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 30:2218-26. 2012
    ..One of the first commercially available GEP tests, a 21-gene profile, was developed to estimate the benefit of adjuvant chemotherapy for hormone receptor-positive breast cancer (HR-positive BC)...
  17. doi request reprint Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy
    Daniel Canter
    Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Urology 77:160-5. 2011
    ..To evaluate the proportion of patients with muscle-invasive urothelial carcinoma (UC) who would be eligible to receive cisplatin-based chemotherapy before and after radical cystectomy based on renal function...
  18. pmc Pathologic concordance of sporadic synchronous bilateral renal masses
    Jason Rothman
    Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 72:138-42. 2008
    ....
  19. pmc Preoperative delays in the US Medicare population with breast cancer
    Richard J Bleicher
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 30:4485-92. 2012
    ....
  20. pmc Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database
    Alexander Kutikov
    Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Urol 186:805-10. 2011
    ..We assessed whether incidental screening due to imaging performed for other purposes has resulted in earlier detection or better outcomes in patients with adrenocortical carcinoma...
  21. pmc Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices
    Yu Ning Wong
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111, USA
    Oncologist 15:566-76. 2010
    ..The influence of cost on the treatment choices of patients with life-threatening illness, such as cancer, is unknown...
  22. ncbi request reprint Early stopping designs based on progression-free survival at an early time point in the initial cohort
    Samuel Litwin
    Biostatistics Facility, Population Science Division, Fox Chase Cancer Center, 333 Central Avenue, Philadelphia, PA 19111, USA
    Stat Med 26:4400-15. 2007
    ..No distributional assumptions are needed other than the binomial, so the design provides rigorous power analysis for this type of study. Tables of optimal designs are supplied for a broad range of requirements...
  23. doi request reprint Adrenocortical carcinoma masquerading as a benign adenoma on computed tomography washout study
    Jay Simhan
    Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 79:e19-20. 2012
    ..We present a case of a 5-cm adrenal lesion with computed tomography washout characteristics consistent with a benign adenoma, which proved upon resection to be an adrenocortical carcinoma...
  24. pmc Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer
    Michael J Hassett
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:5553-60. 2008
    ....
  25. pmc Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma
    Yu Ning Wong
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 30:3545-51. 2012
    ..We conducted a randomized, noncomparative phase II study to measure the efficacy of cetuximab with or without paclitaxel in patients with previously treated urothelial cancer...
  26. pmc Integration of prostate cancer clinical data using an ontology
    Hua Min
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Biomed Inform 42:1035-45. 2009
    ..As the results of the integration process, the semantic query language SPARQL is applied to perform the integrated queries across the two database systems based on PCO...
  27. pmc Predicting growth of solid renal masses under active surveillance
    Paul L Crispen
    Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Urol Oncol 26:555-9. 2008
    ..Here we evaluate factors that may help predict radiographic growth during observation...
  28. pmc Sensitivity analysis to investigate the impact of a missing covariate on survival analyses using cancer registry data
    Brian L Egleston
    Biostatistics Facility, Fox Chase Cancer Center, Philadelphia, PA, USA
    Stat Med 28:1498-511. 2009
    ..We found that surgery was protective, but that the magnitude of the effect depended on assumptions about the relationship of grade with missingness...
  29. ncbi request reprint Decrease in racial disparities in the staging evaluation for prostate cancer after publication of staging guidelines
    Nitya Abraham
    New York University School of Medicine, New York, New York 10016, USA
    J Urol 178:82-7; discussion 87. 2007
    ....